ZBH · Zimmer Biomet Holdings, Inc.

Summary

Zimmer Biomet increases share repurchase expectations to up to $1 billion for fiscal year 2026, a $250 million increase from prior assumption.

Key takeaways

• Company now expects to repurchase up to $1 billion of common stock in FY2026, up $250 million from prior guidance.
• Repurchases will be made under existing $1.5 billion authorization approved in February 2026.
• No changes to the size, duration or terms of the existing authorization.
• Repurchases may be executed in open market or through structured agreements, subject to market conditions and capital availability.